drugset / Trial / NCT07824895
Mazdutide for Weight Management and Gout in Adults With Obesity
Phase 4
Not yet recruiting
30 enrolled
Hongwei Jiang
Second Affiliated Hospital, Zhejiang University, School of Medicine · collabShanghai 10th People's Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open-label, pre-post controlled study to evaluate the effect of Mazdutide on the annualized flare rate (AFR) in adults with obesity and gout. The study will enroll 30 subjects aged 18 to 65 years with a Body Mass Index (BMI) ≥ 30.0 kg/m². Eligible participants must have a confirmed diagnosis of gout and a history of at least 2 gout flares in the past 6 months. The primary objective is to compare the AFR during the 52-week treatment period with the 12 months prior to treatment. All subjects will receive Mazdutide with a dose-escalation regimen, and their outcomes will be compared to their own baseline data.
Timeline
- Start
- 2026-09-15
- Primary completion
- 2027-12-31
- Completion
- 2028-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mazdutide | Protein / enzyme biologic | 9 mg | Subcutaneous |